The Challenge of Selecting Without Complete Information
Not every PFAS-affected water supply comes with a detailed compound inventory. Private wells may have been tested only for a limited panel of compounds, or not tested at all. Small community water systems may have conducted initial PFAS screening with a basic analytical method that covers PFOS and PFOA but not the broader compound universe. Source waters near novel contamination sources — emerging industrial facilities, recently identified biosolid sites — may not yet have been characterized with appropriate methods. In all of these situations, treatment technology selection must proceed with incomplete compound profile information.
A risk-based decision framework for technology selection under uncertainty should address two questions. First, given what is known about the likely contamination source, what is the probable compound profile? Source type provides strong probabilistic information about compound class distribution even when analytical data is limited. Second, given the uncertainty about the full compound profile, which technology offers the best performance hedge against the range of compounds that might be present? This second question favors broad-spectrum technology when the uncertainty range includes short-chain PFAS compounds that conventional media handles poorly.
Source-Type Heuristics for Compound Profile Prediction
Even without compound-level analytical data, the nature of the contamination source provides actionable information about the probable PFAS profile. Agricultural biosolid applications in the vicinity of the water source suggest a short-chain-dominant profile with PFBS, PFPeA, and PFHxA as likely primary compounds. Military base or airport proximity suggests an AFFF-derived profile with PFOS, PFHxS, and fluorotelomer compounds prominent. Industrial zones with fluorochemical manufacturing or processing suggest short-chain PFCAs and potentially PFAE structures. Multiple industrial source types in proximity suggest a diverse mixed profile.
This source-type heuristic approach is not a substitute for analytical data, but it provides a basis for preliminary technology selection while analytical work is underway. A well owner within a known biosolid application zone who is awaiting compound-level analytical results can make a preliminary technology selection favoring short-chain PFAS removal capability based on source-type reasoning, then confirm the decision when analytical data is available.
The Conservative Choice Principle
When compound profile uncertainty is high, risk-based decision theory supports the conservative choice: technology that performs adequately across the broadest possible range of compounds, even if that technology is not optimal for any specific subset of compounds. This principle applies directly to PFAS filter selection. GAC optimized for PFOS removal may be the cost-minimizing choice if source water turns out to contain predominantly PFOS. But if source water contains significant short-chain PFAS, GAC will provide inadequate protection. PFAS-selective broad-spectrum media performs adequately for both long-chain and short-chain compounds, making it the conservative choice when compound profile is unknown.
The cost of the conservative choice — the marginal additional expense of PFAS-selective media compared with standard GAC — should be evaluated against the cost of technology failure: installing inadequate treatment, discovering the failure through water quality monitoring or health outcomes, and then paying to replace the system. When the risk-adjusted expected cost of technology failure exceeds the marginal cost of the conservative choice, the conservative choice is also the economically rational one. For most residential and small-system PFAS treatment contexts, this calculation favors PFAS-selective media.
Staged Decision-Making: Interim Protection with Future Optimization
A staged decision approach combines the conservative choice principle with a plan for decision refinement as information improves. In the first stage, select and install broad-spectrum PFAS-selective media to provide immediate protection against the range of compounds that might be present. In the second stage, conduct comprehensive source water analysis — including a broad analytical panel covering short-chain PFAS, and potentially a TOP assay to characterize precursor loading — to characterize the actual compound profile. In the third stage, use the compound-level data to optimize media selection, sizing, and replacement scheduling for the specific compounds present.
This staged approach avoids the paralysis that can result from deferring treatment installation pending complete analytical characterization, which may take months or years. Immediate installation of broad-spectrum technology provides protection during the characterization phase, and the data generated during initial operation — including effluent monitoring for a broad compound panel — contributes to the optimization decision that follows.
Documentation and the Risk-Management Record
For industrial operators, utilities, and even residential users who may face future questions about the adequacy of their PFAS treatment decisions, documentation of the decision process is a component of risk management. A written decision record that captures the source-type reasoning used in the absence of compound-level data, the technology selected and its known performance characteristics, the plan for confirmatory analytical work, and the monitoring program implemented to verify ongoing performance provides a defensible record of risk-based decision-making under uncertainty.
The documentation requirement is not bureaucratic formalism — it reflects the reality that PFAS liability is an evolving legal landscape where the adequacy of past decisions will be evaluated against the standards of care available at the time those decisions were made. A documented risk-based framework for technology selection under uncertainty is stronger evidence of due diligence than an undocumented decision, even if both led to the same technology choice. As regulatory standards and analytical capabilities continue to develop, the bar for demonstrating adequate PFAS treatment will rise, and the documentation of the decision process will become increasingly important.